Biotechnology company Moderna (NASDAQ:MRNA) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling 35.3% year on year to $108 million. The company’s full-year revenue ...

This study examines jetMESSENGER ® mRNA transfection reagent, a chemical-based reagent for mRNA transfection, as a potential option to conventional approaches. In conclusion, jetMESSENGER ...

This research investigates how to optimize mRNA transfection in human T-cells utilizing the jetMESSENGER ® transfection reagent. By using advanced bioanalytical instruments like the Incucyte ...

Following the COVID-19 pandemic, mRNA-based vaccines have been shown to provide rapid and precise immune responses, however, this technology has much wider applications. Many leading pharma and ...

Moderna is currently in the very early stages of testing a bird flu vaccine using the same mRNA technology that allowed for rapid development and rollout of COVID-19 vaccines. The funds from the ...

Lipid nanoparticle (LNP) mRNA vaccines emerged during the COVID-19 pandemic to form an almost miraculous protection against a virus, which killed millions around the world. Aided by expedited ...

Helen Branswell covers issues broadly related to infectious diseases, including outbreaks, preparedness, research, and vaccine development. Follow her on Mastodon and Bluesky. You can reach Helen ...

Moderna's mRNA technology gained rapid validation as sales of its covid vaccine soared in 2021 and 2022, but we think the firm has yet to secure a narrow economic moat around its business ...

Such premature stop codons account for around 11% of all inherited diseases, including cystic fibrosis and muscular dystrophy. Scientists found that horses developed the ability to run through this ...

Apr. 25, 2025 — Chimpanzee naive pluripotent stem cells (PSCs) can now be grown in cellular cultures, reveals a recent study. They successfully created chimpanzee early embryo models, called ...